The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions

Annals of Clinical Psychiatry

Volumn 24, Issue 1, 2012, Pages 91-109

  Ramasubbu, Rajamannar ^a   Taylor, Valerie H ^c   Samaan, Zainab ^e   Sockalingham, Sanjeev ^c   Li, Madeline ^b   Patten, Scott ^a   Rodin, Gary ^b   Schaffer, Ayal ^c   Beaulieu, Serge ^d   McIntyre, Roger S ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Bipolar disorder; Cancer; Cerebrovascular disease; Comorbidity; Coronary heart disease; Epilepsy; HCV; HIV; Major depressive disorder; Migraine; Multiple sclerosis; Osteoporosis

Indexed keywords

ALPHA INTERFERON; ALPRAZOLAM; AMANTADINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DEXAMPHETAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; METHYLPHENIDATE; MIANSERIN; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; PREDNISONE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

CANADIAN NETWORK FOR MOOD AND ANXIETY TREATMENTS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COGNITIVE THERAPY; COMORBIDITY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR DEPRESSION; MENTAL HEALTH CARE; MIGRAINE; MOOD DISORDER; MULTIPLE SCLEROSIS; NEOPLASM; OSTEOPOROSIS; POSTSTROKE DEPRESSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; ADULT; ADVISORY COMMITTEE; CANADA; CHRONIC DISEASE; PSYCHOLOGICAL ASPECT;

ADULT; ADVISORY COMMITTEES; ANTIDEPRESSIVE AGENTS; CANADA; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHRONIC DISEASE; COMORBIDITY; EPILEPSY; HEPATITIS C; HIV INFECTIONS; HUMANS; MIGRAINE DISORDERS; MOOD DISORDERS; MULTIPLE SCLEROSIS; NEOPLASMS; OSTEOPOROSIS;

EID: 84861434806     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (317)

1. Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med. 2006;21:30-38.
2. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry. 2003;54:227-240. (Pubitemid 37267853)
3. Rugulies R. Depression as a predictor for coronary heart disease. a review and meta-analysis. Am J Prev Med. 2002;23:51-61. (Pubitemid 34687133)
4. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 2006;27:2763-2774. (Pubitemid 44871461)
5. Laursen TM, Munk-Olsen T, Nordentoft M, et al. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007;68:899-907. (Pubitemid 47015490)
6. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:E1-E211.
7. Anderson JL, Adams CD, Antman EM, et al American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148-e304.
8. Gibbons RJ, Abrams J, Chatterjee K, et al American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159-168. (Pubitemid 36044419)
9. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118:1768-1775.
10. Frasure-Smith N, Lespérance F, Prince RH, et al. Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. Lancet. 1997;350:473-479. (Pubitemid 27343302)
11. Jones DA, West RR. Psychological rehabilitation after myocardial infarction: multicentre randomised controlled trial. BMJ. 1996;313:1517-1521. (Pubitemid 27016887)
12. Saab PG, Bang H, Williams RB, et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. J Psychosom Res. 2009;67:45-56.
13. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med. 1996;156:745-752. (Pubitemid 26108196)
14. Dusseldorp E, van Elderen T, Maes S, et al. A meta-analysis of psychoeducational programs for coronary heart disease patients. Health Psychol. 1999;18:506-519. (Pubitemid 29468523)
15. Linden W, Phillips MJ, Leclerc J. Psychological treatment of cardiac patients: a meta-analysis. Eur Heart J. 2007;28:2972-2984. (Pubitemid 350262269)
16. Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med. 2000;62:783-789.
17. Glassman AH, O'Connor CM, Califf RM, et al Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701-709. (Pubitemid 34848222)
18. Lespérance F, Frasure-Smith N, Koszycki D, et al CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297:367-379. (Pubitemid 46155798)
19. Honig A, Kuyper AM, Schene AH, et al; MIND-IT investigators. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69:606-613. (Pubitemid 47463817)
20. Thombs BD, de Jonge P, Coyne JC, et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA. 2008;300:2161-2171.
21. Carney RM, Freedland KE, Miller GE, et al. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res. 2002;53:897-902. (Pubitemid 35282619)
22. Thomas AJ, Kalaria RN, O'Brien JT. Depression and vascular disease: what is the relationship? J Affect Disord. 2004;79:81-95. (Pubitemid 38340532)
23. Everson-Rose SA, Lewis TT. Psychosocial factors and cardiovascular diseases. Annu Rev Public Health. 2005;26:469-500. (Pubitemid 40547393)
24. Laursen TM, Munk-Olsen T, Agerbo E, et al. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry. 2009;66:713-720.
25. Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation. 2001;104:2024-2028. (Pubitemid 33027041)
26. Taylor CB, Conrad A, Wilhelm FH, et al. Psychophysiological and cortisol responses to psychological stress in depressed and nondepressed older men and women with elevated cardiovascular disease risk. Psychosom Med. 2006;68:538-546. (Pubitemid 44297649)
27. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000;20:137-140. (Pubitemid 30202354)
28. Serebruany VL, Glassman AH, Malinin AI, et al. Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul Fibrinolysis. 2003;14:563-567. (Pubitemid 37083172)
29. Sherwood A, Hinderliter AL, Watkins LL, et al. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am Coll Cardiol. 2005;46:656-659. (Pubitemid 41132693)
30. Lespérance F, Frasure-Smith N, Théroux P, et al. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry. 2004;161:271-277. (Pubitemid 38419278)
31. Empana JP, Sykes DH, Luc G, et al PRIME Study Group. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2005;111:2299-2305. (Pubitemid 40647064)
32. Robinson RG, Spalletta G. Poststroke depression: a review. Can J Psychiatry. 2010;55:341-349.
33. World Health Organization. The global burden of disease: 2004 update. http://www.who.int/healthinfo/global-burden-disease/2004-report-update/en/index. html. Geneva, Switzerland: World Health Organization; 2008. Accessed July 16, 2009.
34. House A, Dennis M, Mogridge L, et al. Mood disorders in the year after first stroke. Br J Psychiatry. 1991;158:83-92.
35. Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry. 2003;54:376-387. (Pubitemid 37267864)
36. Ramasubbu R. Relationship between depression and cerebrovascular disease: conceptual issues. J Affect Disord. 2000;57:1-11. (Pubitemid 30119952)
37. Robinson RG. Post stroke mania: prevalence and clinical symptoms. In: Robinson RG. The clinical neuropsychiatry of stroke: cognitive, behavioral, and emotional disorders following vascular brain injury. Cambridge, United Kingdom: Cambridge University Press; 1998:303-312.
38. Burvill PW, Johnson GA, Jamrozik KD, et al. Prevalence of depression after stroke: the Perth Community Stroke Study. Br J Psychiatry. 1995;166:320-327.
39. Parikh RM, Robinson RG, Lipsey JR, et al. The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol. 1990;47:785-789. (Pubitemid 20208619)
40. Robinson RG, Bolla-Wilson K, Kaplan E, et al. Depression influences intellectual impairment in stroke patients. Br J Psychiatry. 1986;148:541-547. (Pubitemid 16042300)
41. Morris PL, Robinson RG, Samuels J. Depression, introversion and mortality following stroke. Aust N Z J Psychiatry. 1993;27:443-449. (Pubitemid 23344645)
42. Stenager EN, Madsen C, Stenager E, et al. Suicide in patients with stroke: epidemiological study. BMJ. 1998;316:1206. (Pubitemid 28171335)
43. Ramasubbu R, Patten SB. Effect of depression on stroke morbidity and mortality. Can J Psychiatry. 2003;48:250-257. (Pubitemid 36733832)
44. Larson SL, Owens PL, Ford D, et al. Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke. 2001;32:1979-1983. (Pubitemid 32878509)
45. Whyte EM, Mulsant BH. Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry. 2002;52:253-264. (Pubitemid 35232092)
46. Ramasubbu R, Tobias R, Bech-Hansen NT. Extended evaluation of serotonin transporter gene functional polymorphisms in subjects with post-stroke depression. Can J Psychiatry. 2008;53:197-201. (Pubitemid 351469379)
47. Kohen R, Cain KC, Mitchell PH, et al. Association of serotonin transporter gene polymorphisms with poststroke depression. Arch Gen Psychiatry. 2008;65:1296-1302.
48. Spalletta G, Bossù P, Ciaramella A, et al. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry. 2006;11:984-991. (Pubitemid 44631641)
49. Robinson RG. Mechanisms of post stroke depression. In: Robinson RG. The clinical neuropsychiatry of stroke: cognitive, behavioral, and emotional disorders following vascular brain injury. Cambridge, United Kingdom: Cambridge University Press; 1998:254-281.
50. Eastwood MR, Rifat SL, Nobbs H, et al. Mood disorder following cerebrovascular accident. Br J Psychiatry. 1989;154:195-200. (Pubitemid 19050159)
51. Tenev VT, Robinson RG, Jorge RE. Is family history of depression a risk factor for poststroke depression? Meta-analysis. Am J Geriatr Psychiatry. 2009;17:276-280.
52. Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008;CD003437.
53. Chen Y, Guo JJ, Zhan S, et al. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother. 2006;40:2115-2122. (Pubitemid 44954428)
54. Anderson G, Vestergaard K, Lauritzen L. Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke. 1994;25:1099-1104. (Pubitemid 24164745)
55. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke. 2000;31:1829-1832. (Pubitemid 30620458)
56. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351-359. (Pubitemid 30145919)
57. Fruehwald S, Gatterbauer E, Rehak P, et al. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol. 2003;250:347-351. (Pubitemid 36399276)
58. Murray V, von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry. 2005;66:708-716. (Pubitemid 40942416)
59. Lipsey JR, Robinson RG, Pearlson GD, et al. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet. 1984;1:297-300. (Pubitemid 14185332)
60. Grade C, Redford B, Chrostowski J, et al. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil. 1998;79:1047-1050. (Pubitemid 28419310)
61. Hackett ML, Anderson CS, House A, et al. Interventions for preventing depression after stroke. Cochrane Database Syst Rev. 2008;CD003689.
62. Chen Y, Patel NC, Guo JJ, et al. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007;22:159-166. (Pubitemid 46559872)
63. Yi ZM, Liu F, Zhai SD. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. Int J Clin Pract. 2010;64:1310-1317.
64. Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA. 2008;299:2391-2400. (Pubitemid 351749237)
65. Fullerton AG, Agerholm M. Side-effects of nortriptyline treatment for poststroke depression. Lancet. 1984;323:519-520. (Pubitemid 14193157)
66. Jiang B, Lu W, Song X-W, et al. The effect of post stroke depression interventions on the recovery of neurological function. Modern Rehabilitation. 2001;5:29-30.
67. Rampello L, Alvano A, Chiechio S, et al. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study. Arch Gerontol Geriatr. 2005;40:275-285. (Pubitemid 40462249)
68. Reding MJ, Orto LA, Winter SW, et al. Antidepressant therapy after stroke. A double-blind trial. Arch Neurol. 1986;43:763-765. (Pubitemid 16034221)
69. DeVane CL, Markowitz JS. Avoiding psychotropic drug interactions in the cardiovascular patient. Bull Menninger Clin. 2000;64:49-59. (Pubitemid 30091583)
70. Sacchetti E, Turrina C, Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf. 2010;33:273-288.
71. Murray GB, Shea V, Conn DR. Electroconvulsive therapy for post-stroke depression. J Clin Psychiatry. 1987;47:258-260.
72. Jorge RE, Robinson RG, Tateno A, et al. Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. Biol Psychiatry. 2004;55:398-405. (Pubitemid 38199990)
73. Lo C, Li M, Rodin G. The assessment and treatment of distress in cancer patients: overview and future directions. Minerva Psichiatr. 2008;49:129-143.
74. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004:57-71.
75. Brintzenhofe-Szoc KM, Levin TT, Li Y, et al. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics. 2009;50:383-391.
76. Rodin G, Zimmermann C, Rydall A, et al. The desire for hastened death in patients with metastatic cancer. J Pain Symptom Manage. 2007;33:661-675. (Pubitemid 46783994)
77. Pirl WF. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr. 2004;32:32-39.
78. Lo C, Zimmermann C, Rydall A, et al. Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. J Clin Oncol. 2010;28:3084-3089.
79. Benton T, Staab J, Evans DL. Medical comorbidity in depressive disorders. Ann Clin Psychiatry. 2007;19:289-303.
80. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009;190:S54-S60.
81. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105. (Pubitemid 37432885)
82. Grassi L, Indelli M, Marzola M, et al. Depressive symptoms and quality of life in home-care-assisted cancer patients. J Pain Symptom Manage. 1996;12:300-307. (Pubitemid 26362304)
83. Chochinov HM, Wilson KG, Enns M, et al. Depression, hopelessness, and suicidal ideation. Psychosomatics. 1998;39:366-370.
84. Colleoni M, Mandala M, Peruzzotti G, et al. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356:1326-1327.
85. Chen ML, Chang HK. Physical symptom profiles of depressed and nondepressed patients with cancer. Palliat Med. 2004;18:712-718.
86. Prieto JM, Blanch J, Atala J, et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol. 2002;20:1907-1917. (Pubitemid 34273283)
87. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40:1797-1810.
88. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer. 2009;115:5349-5361.
89. Lloyd-Williams M, Shiels C, Taylor F, et al. Depression-an independent predictor of early death in patients with advanced cancer. J Affect Disord. 2009;113:127-132.
90. Iosifescu DV. Treating depression in the medically ill. Psychiatr Clin North Am. 2007;30:77-90. (Pubitemid 46386305)
91. Li M, Boquiren V, Lo C, et al. Depression and anxiety in supportive oncology. In: Davis MP, Feyer P, Ortner P, et al, eds. Supportive oncology. Philadelphia, PA: Saunders; 2011:528-538.
92. Garssen B. Psychological factors and cancer development: evidence after 30 years of research. Clin Psychol Rev. 2004;24:315-338. (Pubitemid 38881545)
93. Nausheen B, Carr NJ, Peveler RC, et al. Relationship between loneliness and proangiogenic cytokines in newly diagnosed tumors of colon and rectum. Psychosom Med. 2010;72:912-916.
94. Miller AH, Ancoli-Israel S, Bower JE, et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26:971-982. (Pubitemid 351409339)
95. Jacobsen PB, Donovan KA, Swaine AN, et al. Management of anxiety and depression in adult cancer patients: toward an evidence-based approach. In: Chang AE, Ganz PA, Kinsella TJ, et al, eds. Oncology: an evidence-based approach. New York, NY: Springer-Verlag; 2006:1552-1579.
96. Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer. 2006;94:372-390. (Pubitemid 43237562)
97. Rodin G, Lloyd N, Katz M, et al. The treatment of depression in cancer patients: a systematic review. Support Care Cancer. 2007;15:123-136. (Pubitemid 46332931)
98. Ng CG, Boks MP, Zainal NZ, et al. The prevalence and pharmacotherapy of depression in cancer patients. J Affect Disord. 2010;131:1-7.
99. Jacobsen PB, Jim HS. Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges. CA Cancer J Clin. 2008;58:214-230.
100. Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer. 1999;80:1770-1780. (Pubitemid 29389631)
101. Andrykowski MA, Manne SL. Are psychological interventions effective and accepted by cancer patients? I. Standards and levels of evidence. Ann Behav Med. 2006;32:93-97. (Pubitemid 44547589)
102. Lepore SJ, Coyne JC. Psychological interventions for distress in cancer patients: a review of reviews. Ann Behav Med. 2006;32:85-92. (Pubitemid 44547588)
103. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11-28.
104. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003;21:4635-4641. (Pubitemid 46594038)
105. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-966. (Pubitemid 32240314)
106. Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2005;89:243-249. (Pubitemid 43293071)
107. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat. 2001;70:1-10. (Pubitemid 33105097)
108. Musselman DL, Somerset WI, Guo Y, et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry. 2006;67:288-296. (Pubitemid 43357477)
109. Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008;112:197-201.
110. Razavi D, Allilaire JF, Smith M, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand. 1996;94:205-210. (Pubitemid 26313295)
111. Holland JC, Romano SJ, Heiligenstein JH, et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology. 1998;7:291-300. (Pubitemid 28381139)
112. Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol. 2003;21:1937-1943. (Pubitemid 46606381)
113. Lydiatt WM, Denman D, McNeilly DP, et al. A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008;134:528-535.
114. Costa D, Mogos I, Toma T. Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand. 1985; 320:85-92. (Pubitemid 16219447)
115. van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry. 1996;169:440-443.
116. Tarrier N, Maguire P. Treatment of psychological distress following mastectomy: an initial report. Behav Res Ther. 1984;22:81-84. (Pubitemid 14193529)
117. Ersoy MA, Noyan AM, Elbi H. An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients. Clin Drug Investig. 2008;28:113-120.
118. Kim SW, Shin IS, Kim JM, et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008;62:75-83.
119. Moss EL, Simpson JS, Pelletier G, et al. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology. 2006;15:259-267.
120. Holland JC, Morrow GR, Schmale A, et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol. 1991;9:1004-1011.
121. Wald TG, Kathol RG, Noyes R Jr, et al. Rapid relief of anxiety in cancer patients with both alprazolam and placebo. Psychosomatics. 1993;34:324-332. (Pubitemid 23199408)
122. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep. 1985;69:751-754. (Pubitemid 15229409)
123. Fernandez F, Adams F, Holmes VF, et al. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics. 1987; 28:455-461. (Pubitemid 18039023)
124. Homsi J, Nelson KA, Sarhill N, et al. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care. 2001;18:403-407.
125. Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manage. 1998;16:193-198. (Pubitemid 28429068)
126. Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics. 1996;37:57-62. (Pubitemid 26021821)
127. Natenshon AL. Clinical evaluation of Ritalin. Dis Nerv Syst. 1956;17:392-396.
128. Bruera E, Carraro S, Roca E, et al. Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients. Cancer Treat Rep. 1986;70:295-298. (Pubitemid 16166181)
129. Arakawa S. Relaxation to reduce nausea, vomiting, and anxiety induced by chemotherapy in Japanese patients. Cancer Nurs. 1997;20:342-349. (Pubitemid 27494806)
130. Bindemann S, Soukop M, Kaye SB. Randomised controlled study of relaxation training. Eur J Cancer. 1991;27:170-174.
131. Edgar L, Rosberger Z, Collet JP. Lessons learned: Outcomes and methodology of a coping skills intervention trial comparing individual and group formats for patients with cancer. Int J Psychiatry Med. 2001;31:289-304. (Pubitemid 34121041)
132. Fawzy FI, Kemeny ME, Fawzy NW, et al. A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch Gen Psychiatry. 1990;47:729-735. (Pubitemid 20229963)
133. Petersen RW, Quinlivan JA. Preventing anxiety and depression in gynaecological cancer: a randomised controlled trial. BJOG. 2002;109:386-394. (Pubitemid 37338015)
134. Ando M, Morita T, Akechi T, et al. The efficacy of mindfulness-based meditation therapy on anxiety, depression, and spirituality in Japanese patients with cancer. J Palliat Med. 2009;12:1091-1094.
135. Burish TG, Carey MP, Krozely MG, et al. Conditioned side effects induced by cancer chemotherapy: prevention through behavioral treatment. J Consult Clin Psychol. 1987;55:42-48.
136. Burish TG, Lyles JN. Effectiveness of relaxation training in reducing adverse reactions to cancer chemotherapy. J Behav Med. 1981;4:65-78. (Pubitemid 12238235)
137. Jacobsen PB, Meade CD, Stein KD, et al. Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol. 2002;20:2851-2862. (Pubitemid 34651514)
138. Mantovani G, Astara G, Lampis B, et al. Evaluation by multidimensional instruments of health-related quality of life of elderly cancer patients undergoing three different "psychosocial" treatment approaches. A randomized clinical trial. Support Care Cancer. 1996;4:129-140. (Pubitemid 126469097)
139. Decker TW, Cline-Elsen J, Gallagher M. Relaxation therapy as an adjunct in radiation oncology. J Clin Psychol. 1992;48:388-393.
140. Evans RL, Connis RT. Comparison of brief group therapies for depressed cancer patients receiving radiation treatment. Public Health Rep. 1995;110:306-311.
141. Pruitt BT, Waligora-Serafin B, McMahon T, et al. An educational intervention for newly-diagnosed cancer patients undergoing radiotherapy. Psychooncology. 1993;2:55-62.
142. Simpson JS, Carlson LE, Trew ME. Effect of group therapy for breast cancer on healthcare utilization. Cancer Pract. 2001;9:19-26. (Pubitemid 32106699)
143. Liossi C, White P. Efficacy of clinical hypnosis in the enhancement of quality of life of terminally ill cancer patients. Contemp Hypn. 2001;18:145-160.
144. McQuellon RP, Wells M, Hoffman S, et al. Reducing distress in cancer patients with an orientation program. Psychooncology. 1998;7:207-217. (Pubitemid 28267060)
145. McArdle JM, George WD, McArdle CS, et al. Psychological support for patients undergoing breast cancer surgery: a randomised study. BMJ (Clinical research ed). 1996;312:813-816. (Pubitemid 26099300)
146. Rawl SM, Given BA, Given CW, et al. Intervention to improve psychological functioning for newly diagnosed patients with cancer. Oncol Nurs Forum. 2002;29:967-975.
147. Watson M, Denton S, Baum M, et al. Counselling breast cancer patients: a
148. Kissane DW, Grabsch B, Clarke DM, et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology. 2007;16:277-286. (Pubitemid 46681097)
149. Edelman S, Bell DR, Kidman AD. A group cognitive behaviour therapy programme with metastatic breast cancer patients. Psychooncology. 1999;8:295-305. (Pubitemid 29417485)
150. Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001;345:1719-1726.
151. Pitceathly C, Maguire P, Fletcher I, et al. Can a brief psychological intervention prevent anxiety or depressive disorders in cancer patients? A randomised controlled trial. Ann Oncol. 2009;20:928-934.
152. Marchioro G, Azzarello G, Checchin F, et al. The impact of a psychological intervention on quality of life in non-metastatic breast cancer. Eur J Cancer. 1996;32A:1612-1615. (Pubitemid 26279133)
153. Savard J, Simard S, Giguere I, et al. Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects. Palliat Support Care. 2006;4:219-237.
154. UNAIDS. UNAIDS report on the global AIDS epidemic. 2010. http://www.unaids.org/globalreport/global-report.htm. Accessed May 19, 2011.
155. Brown GR, Rundell JR, McManis SE, et al. Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom Med. 1992;54:588-601.
156. Dew MA, Becker JT, Sanchez J, et al. Prevalence and predictors of depressive, anxiety and substance use disorders in HIV-infected and uninfected men: a longitudinal evaluation. Psychol Med. 1997;27:395-409. (Pubitemid 27139972)
157. Avants SK, Margolin A, Warburton LA, et al. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addict. 2001;10:69-78. (Pubitemid 32201734)
158. Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573-580. (Pubitemid 36577260)
159. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285:1466-1474. (Pubitemid 32221895)
160. Yun LW, Maravi M, Kobayashi JS, et al. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38:432-438. (Pubitemid 40381553)
161. Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms. Gen Hosp Psych. 1997;19:89-97. (Pubitemid 27146816)
162. Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatry. 1998;55:452-457. (Pubitemid 28237279)
163. Atkinson JH, Heaton RK, Patterson TL, et al. Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord. 2008;108:225-234. (Pubitemid 351615444)
164. Alciati A, Gallo L, Monforte AD, et al. Major depression-related immunological changes and combination antiretroviral therapy in HIV-seropositive patients. Hum Psychopharmacol. 2007;22:33-40. (Pubitemid 46178776)
165. Evans DL, Ten Have TR, Douglas SD, et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry. 2002;159:1752-1759.
166. Lochet P, Peyriere H, Lotthe A, et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003;4:62-66. (Pubitemid 37161538)
167. O'Mahony SM, Myint AM, Steinbusch H, et al. Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation. 2005;12:293-298. (Pubitemid 41318212)
168. Himelhoch S, Medoff DR. Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS. 2005;19:813-822. (Pubitemid 43100336)
169. Rabkin JG, Rabkin R, Harrison W, et al. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry. 1994;151:516-523. (Pubitemid 24115815)
170. Fernandez F, Levy JK, Samley HR, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med. 1995;25:53-67.
171. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2000;61:436-440. (Pubitemid 30452211)
172. Rabkin JG, McElhiney MC, Rabkin R, et al. Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. J Clin Psychiatry. 2010;71:707-715.
173. Elliott AJ, Uldall KK, Bergam K, et al. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry. 1998;155:367-372. (Pubitemid 28114894)
174. Schwartz JA, McDaniel JS. Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study. Depress Anxiety. 1999;9:70-74. (Pubitemid 29177716)
175. Currier MB, Molina G, Kato M. Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study. Psychosomatics. 2004;45:210-216. (Pubitemid 38621528)
176. Rabkin JG, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. J Clin Psychiatry. 1994;55:433-439.
177. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther. 2003;25:1200-1210. (Pubitemid 36532587)
178. Chesney MA, Chambers DB, Taylor JM, et al. Coping effectiveness training for men living with HIV: results from a randomized clinical trial testing a group-based intervention. Psychosom Med. 2003;65:1038-1046. (Pubitemid 38057805)
179. Kelly JA, Murphy DA, Bahr GR, et al. Outcome of cognitive-behavioral and support group brief therapies for depressed, HIV-infected persons. Am J Psychiatry. 1993;150:1679-1686. (Pubitemid 23325951)
180. Markowitz JC, Klerman GL, Clougherty KF, et al. Individual psychotherapies for depressed HIV-positive patients. Am J Psychiatry. 1995;152:1504-1509.
181. Hepatitis C: global prevalence. Wkly Epidemiol Rec. 1997;72:341-344.
182. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol. 2007;21(suppl C):25C-34C. (Pubitemid 47177083)
183. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171. (Pubitemid 38428955)
184. el-Serag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476-482. (Pubitemid 34827192)
185. Wichers MC, Koek GH, Robaeys G, et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005;10:538-544. (Pubitemid 40897037)
186. Capuron L, Pagnoni G, Demetrashvili M, et al. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry. 2005;58:190-196. (Pubitemid 41112266)
187. Wichers MC, Kenis G, Koek GH, et al. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res. 2007;62:207-214. (Pubitemid 46161588)
188. Gleason OC, Yates WR, Isbell MD, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002;63:194-198. (Pubitemid 34407077)
189. Gleason OC, Yates WR, Philipsen MA. Major depressive disorder in hepatitis C: an open-label trial of escitalopram. Prim Care Companion J Clin Psychiatry. 2005;7:225-230. (Pubitemid 41702850)
190. Morasco BJ, Rifai MA, Loftis JM, et al. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007;103:83-90. (Pubitemid 47445756)
191. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25:1163-1174. (Pubitemid 46650303)
192. Kronenberger B, Berg T, Herrmann E, et al. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. Eur J Gastroenterol Hepatol. 2007;19:639-646. (Pubitemid 47067061)
193. Quarantini LC, Miranda-Scippa A, Schinoni MI, et al. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. Clin Neuropharmacol. 2006;29:138-143. (Pubitemid 44503891)
194. Schramm TM, Lawford BR, Macdonald GA, et al. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust. 2000;173:359-361.
195. Kalyoncu OA, Tan D, Mirsal H, et al. Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser. J Psychopharmacol. 2005;19:102-105.
196. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol. 1993;88:760-761. (Pubitemid 23132837)
197. Goldman SL. Successful treatment of interferon-alfa-induced depression treated with nortriptyline (letter). Psychosomatics. 1994;35:412-413.
198. Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics. 1999;40:510-512. (Pubitemid 29532016)
199. Malek-Ahmadi P, Ghandour E. Bupropion for treatment of interferon-induced depression. Ann Pharmacother. 2004;38:1202-1205. (Pubitemid 38802162)
200. ICHD-II. The International Classification of Headache Disorders. 2nd ed. Cephalalgia. 2004;24:8-160.
201. Merikangas KR, Stevens DE. Comorbidity of migraine and psychiatric disorders. Neurol Clin. 1997;15:115-123. (Pubitemid 27098703)
202. Breslau N, Davis G, Schultz L, et al. Migraine and major depression: a longitudinal study. Headache. 1994;34:387-393. (Pubitemid 24264281)
203. Breslau N. Psychiatric comorbidity in migraine. Cephalalgia. 1998;18(suppl 22):56-58.
204. Breslau N, Lipton R, Stewart W, et al. Comorbidity of migraine and depression. Investigating potential etiology and prognosis. Neurology. 2003;60:1308-1312. (Pubitemid 36460987)
205. Merikangas KR, Stevens DE, Angst J. Psychopathology and headache syndromes in the community. Headache. 1994;34:S17-S22.
206. Merikangas KR, Angst J, Isler H. Migraine and psychopathology. Results of the Zurich cohort study of young adults. Arch Gen Psychiatry. 1990;47:849-853. (Pubitemid 20302700)
207. Merikangas KR, Risch NJ, Merikangas JR, et al. Migraine and depression: association and familial transmission. J Psychiatr Res. 1988;22:119-129.
208. Lipton R, Hamelsky S, Kolodner K, et al. Migraine, quality of life, and depression. Neurology. 2000;55:629-635.
209. Breslau N, Davis GC. Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults. J Psychiatr Res. 1993;27:211-221. (Pubitemid 23234204)
210. Stewart WF, Shechter A, Liberman J. Physician consultation for headache pain and history of panic: results from a population-based study. Am J Med. 1992;92:35-40.
211. Samaan Z, Farmer A, Craddock N, et al. Migraine in recurrent depression: case-control study. Br J Psychiatry. 2009;194:350-354.
212. Breslau N, Schultz L, Stewart W, et al. Headache and major depression: is the association specific to migraine? Neurology. 2000;54:308-313. (Pubitemid 30078058)
213. Radat F, Swendsen J. Psychiatric comorbidity in migraine: a review. Cephalalgia. 2005;25:165-178. (Pubitemid 40321708)
214. Ziegler DK, Hassanein RS, Kodanaz A, et al. Circadian rhythms of plasma cortisol in migraine. J Neurol Neurosurg Psychiatry. 1979;42:741-748. (Pubitemid 9220277)
215. Merikangas KR, Stevens DE, Merikangas JR, et al. Tyramine conjugation deficit in migraine, tension-type headache, and depression. Biol Psychiatry. 1995;38:730-736.
216. Jarman J, Davies P, Fernandez M, et al. Platelet [3H]imipramine binding in migraine and tension headache in relation to depression. J Psychiatr Res. 1991;25:205-211.
217. D'Andrea G, Welch K, Riddle J, et al. Platelet serotonin metabolism and ultrastructure in migraine. Arch Neurol. 1989;46:1187-1189. (Pubitemid 19268385)
218. Meltzer H, Lowy M. The serotonin hypothesis of depression. In: Meltzer H, ed. Psychopharmacology: the third generation of progress. New York, NY: Raven Press; 1987:513-526.
219. Buchsbaum MS, Coursey RD, Murphy DL. The biochemical high-risk paradigm: behavioural and familial correlates of low platelets monoamine oxidase activity. Science. 1976;194:339-341.
220. Rubino E, Ferrero M, Rainero I, et al. Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis. Cephalalgia. 2009;29:818-825.
221. Samaan Z, Farmer A. Migraine and depression: connecting the dots. Mind and Brain, The Journal of Psychiatry. 2010;1:55-64.
222. Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003;61:375-382. (Pubitemid 36975969)
223. Samaan Z, MacGregor EA, Dowson A, et al. Diagnosing migraine in research and clinical settings: development and validation of the Structured Migraine Interview (SMI). BMC Neurol. 2010;10:7.
224. Lampl C, Schweiger C. Antidepressants for migraine prophylaxis. European Neurological Journal. 2010;2:83-87.
225. Olfoson M, Marcus SC, Druss B, et al. National trends in the outpatient treatment of depression. JAMA. 2002;287:203-209. (Pubitemid 34251945)
226. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ. 2006;332:525-527. (Pubitemid 44364370)
227. World Health Organization, Atlas of multiple sclerosis resources in the world 2008. Geneva, Switzerland: World Health Organization; 2008.
228. Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005;11:328-337.
229. Patten SB, Beck CA, Williams JV, et al. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61:1524-1527. (Pubitemid 37505573)
230. Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry. 1987;9:426-434. (Pubitemid 17165071)
231. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology. 1996;46:628-632. (Pubitemid 26099623)
232. Joffe RT, Lippert GP, Gray TA, et al. Mood disorder and multiple sclerosis. Arch Neurol. 1987;44:376-378. (Pubitemid 17044085)
233. Sadovnick AD, Eisen K, Ebers GC, et al. Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991;41:1193-1196.
234. Bronnum-Hansen H, Stenager E, Nylev Stenager E, et al. Suicide among Danes with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76:1457-1459. (Pubitemid 41360993)
235. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry. 1998;65:56-59. (Pubitemid 28302357)
236. Stenager EN, Stenager E, Koch-Henriksen N, et al. Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry. 1992;55:542-545.
237. Feinstein A, Roy P, Lobaugh N, et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology. 2004;62:586-590. (Pubitemid 38252800)
238. Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531-533. (Pubitemid 27204238)
239. Mohr DC, Goodkin DE, Islar J, et al. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol. 2001;58:1081-1086. (Pubitemid 32660771)
240. Feinstein A, Feinstein K, Gray T, et al. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol. 1997;54:1116-1121. (Pubitemid 27396479)
241. Patten S. Diagnosing depression in MS in the face of overlapping symptoms. Int MS J. 2010;17:3-5.
242. Barak Y, Ur E, Achiron A. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J Neuropsychiatry Clin Neurosci. 1999;11:271-273. (Pubitemid 29224856)
243. Benedetti F, Campori E, Colombo C, et al. Fluvoxamine treatment of major depression associated with multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2004;16:364-366. (Pubitemid 39244565)
244. Scott TF, Nussbaum P, McConnell H, et al. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res. 1995;17:421-422.
245. Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008;30:40-48. (Pubitemid 350299496)
246. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147:1493-1497. (Pubitemid 20365439)
247. Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001;69:942-949. (Pubitemid 33140495)
248. Patten SB. Antidepressant treatment for major depression in multiple sclerosis: the evolving efficacy literature. International Journal of MS Care. 2009;11:174-179.
249. Mohr DC, Goodkin DE. Treatment of depression in multiple sclerosis: review and meta-analysis. Clinical Psychology: Science and Practice. 1999;6:1-9.
250. Schiffer RB, Wineman NM, Weitkamp LR. Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry. 1986;143:94-95. (Pubitemid 16185872)
251. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470-472. (Pubitemid 40470667)
252. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol. 2003;16:165-170. (Pubitemid 36521202)
253. Mula M, Schmitz B, Jauch R, et al. On the prevalence of bipolar disorder in epilepsy. Epilepsy Behav. 2008;13:658-661.
254. Kanner AM. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry. 2003;54:388-398. (Pubitemid 37267865)
255. Mendez MF, Doss RC, Taylor JL, et al. Depression in epilepsy. Relationship to seizures and anticonvulsant therapy. J Nerv Ment Dis. 1993;181:444-447. (Pubitemid 24259619)
256. Hesdorffer DC, Hauser WA, Annegers JF, et al. Major depression is a risk factor for seizures in older adults. Ann Neurol. 2000;47:246-249. (Pubitemid 30078574)
257. Forsgren L, Nyström L. An incident case-referent study of epileptic seizures in adults. Epilepsy Res. 1990;6:66-81. (Pubitemid 20172108)
258. Mendez MF, Engebrit B, Doss R, et al. The relationship of epileptic auras and psychological attributes. J Neuropsychiatry Clin Neurosci. 1996;8:287-292. (Pubitemid 26275740)
259. Gilliam FG, Santos J, Vahle V, et al. Depression in epilepsy: ignoring clinical expression of neuronal network dysfunction? Epilepsia. 2004;45(suppl 2):28-33. (Pubitemid 38856388)
260. Kanner AM. Depression in epilepsy: a complex relation with unexpected consequences. Curr Opin Neurol. 2008;21:190-194. (Pubitemid 351644162)
261. Robertson MM, Trimble MR. Depressive illness in patients with epilepsy: a review. Epilepsia. 1983;24(suppl 2):S109-S116. (Pubitemid 14150269)
262. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 2007;30:555-567. (Pubitemid 47037315)
263. Kalinin VV. Suicidality and antiepileptic drugs: is there a link? Drug Saf. 2007;30:123-142. (Pubitemid 46193063)
264. Jobe PC, Mishra PK, Adams-Curtis LE, et al. The genetically epilepsy-prone rat (GEPR). Ital J Neurol Sci. 1995;16:91-99.
265. Kanner AM. Depression and epilepsy: do glucocorticoids and glutamate explain their relationship? Curr Neurol Neurosci Rep. 2009;9:307-312.
266. Kanner AM. Mood disorder and epilepsy: a neurobiologic perspective of their relationship. Dialogues Clin Neurosci. 2008;10:39-45. (Pubitemid 351542977)
267. Pineda E, Shin D, Sankar R, et al. Comorbidity between epilepsy and depression: experimental evidence for the involvement of serotonergic, glucocorticoid, and neuroinflammatory mechanisms. Epilepsia. 2010;51(suppl 3):110-114.
268. Pisani F, Spina E, Oteri G. Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia. 1999;40(suppl 10):S48-S56.
269. Ruffmann C, Bogliun G, Beghi E. Epileptogenic drugs: a systematic review. Expert Rev Neurother. 2006;6:575-589. (Pubitemid 43764755)
270. Mula M. The clinical spectrum of bipolar symptoms in epilepsy: a critical reappraisal. Postgrad Med. 2010;122:17-23.
271. Mazza M, Di Nicola M, Della Marca G, et al. Bipolar disorder and epilepsy: a bidirectional relation? Neurobiological underpinnings, current hypotheses, and future research directions. Neuroscientist. 2007;13:392-404. (Pubitemid 47062982)
272. Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy. A double-blind trial. J Affect Disord. 1985;9:127-136. (Pubitemid 16240197)
273. Hovorka J, Herman E, Nemcová II. Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy Behav. 2000;1:444-447.
274. Specchio LM, Iudice A, Specchio N, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol. 2004;27:133-136. (Pubitemid 38746014)
275. DeVane CL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol. 1999;19:443-466. (Pubitemid 29283824)
276. Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav. 2007;10:148-154. (Pubitemid 46132163)
277. Fakhoury TA, Miller JM, Hammer AE, et al. Effects of lamotrigine on mood in older adults with epilepsy and comorbid depressive symptoms: an open-label, multicentre, prospective study. Drugs Aging. 2008;25:955-962.
278. Blumer D, Montouris G, Hermann B. Psychiatric morbidity in seizure patients on a neurodiagnostic monitoring unit. J Neuropsychiatry Clin Neurosci. 1995;7:445-456.
279. Ramaratnam S, Baker GA, Goldstein LH. Psychological treatments for epilepsy. Cochrane Database Syst Rev. 2008;(3):CD002029.
280. Davis GR, Armstrong HE Jr, Donovan DM, et al. Cognitive-behavioral treatment of depressed affect among epileptics: preliminary findings. J Clin Psychol. 1984;40:930-935. (Pubitemid 14059657)
281. Martinovic Z, Simonovic P, Djokic R. Preventing depression in adolescents with epilepsy. Epilepsy Behav. 2006;9:619-624. (Pubitemid 44815280)
282. Savard G, Andermann LF, Reutens D, et al. Epilepsy, surgical treatment and postoperative psychiatric complications: a re-evaluation of the evidence. In: Trimble MR, Schmidt B, eds. Forced normalization and alternative psychosis of epilepsy. Petersfield, United Kingdom: Wrightson Biomedical; 1998:179-192.
283. Robertson MM. Forced normalization and the aetiology of depression in epilepsy. In: Trimble MR, Schmidt B, eds. Forced normalization and alternative psychosis of epilepsy. Petersfield, United Kingdom: Wrightson Biomedical; 1998:143-167.
284. Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav. 2000;1:100-105.
285. Sackeim HA. The anticonvulsant hypothesis of the mechanisms of action of ECT: current status. J ECT. 1999;15:5-26. (Pubitemid 29318091)
286. Coffey CE, Lucke J, Weiner RD, et al. Seizure threshold in electroconvulsive therapy (ECT) II. The anticonvulsant effect of ECT. Biol Psychiatry. 1995;37:777-788.
287. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group. Neurology. 1995;45:224-230.
288. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58:364-373. (Pubitemid 41219704)
289. Sawka AM, Thabane L, Papaioannou A, et al. The number of Canadian men and women needed to be screened to detect a case of osteoporosis: a population based study from the Canadian Multicentre Osteoporosis Study (CaMos). J Bone Miner Res. 2004;19:S368.
290. Looker AC, Melton LJ 3rd, Harris TB, et al. Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III. J Bone Miner Res. 2010;25:64-71.
291. Doherty DA, Sanders KM, Kotowicz MA, et al. Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int. 2001;12:16-23. (Pubitemid 32233654)
292. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989;149:2445-2448. (Pubitemid 19283200)
293. Melton LJ 3rd, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res. 1992;7:1005-1010.
294. World Health Organization. The world health report 2001: mental health: new understanding, new hope. Geneva, Switzerland: World Health Organization; 2001.
295. Taylor V, McKinnon MC, Macdonald K, et al. Adults with mood disorders have an increased risk profile for cardiovascular disease within the first two years of treatment. Can J Psychiatry. 2010;55:362-368.
296. Ziere G, Dieleman JP, van der Cammen TJ, et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008;28:411-417.
297. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167:1240-1245. (Pubitemid 46998494)
298. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167:188-194. (Pubitemid 46148067)
299. Cauley JA, Fullman RL, Stone KL, et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int. 2005;16:1525-1537. (Pubitemid 41790856)
300. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Eng J Med. 1996;335:1176-1181. (Pubitemid 26339771)
301. Eskandari F, Martinez PE, Torvik S, et al. Low bone mass in premenopausal women with depression. Arch Intern Med. 2007;167:2329-2336. (Pubitemid 350179528)
302. Petronijevic M, Petronijevic N, Ivkovic M, et al. Low bone mineral density and high bone metabolism turnover in premenopausal women with unipolar depression. Bone. 2008;42:582-590.
303. Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in subjects using central nervous system-active medications. Am J Med. 2005;118:1414.
304. Bolton JM, Targownik LE, Leung S, et al. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol. 2011;31:56-60.
305. Plenge P, Rafaelsen OJ. Lithium effects on calcium, magnesium and phosphate in man: effects on balance, bone mineral content, faecal and urinary excretion. Acta Psychiatr Scand. 1982;66:361-373. (Pubitemid 12006257)
306. Bliziotes MM, Eshleman AJ, Zhang XW, et al. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone. 2001;29:477-486. (Pubitemid 33026469)
307. Battaglino R, Fu J, Spate U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res. 2004;19:1420-1431. (Pubitemid 41094343)
308. Warden SJ, Bliziotes MM, Wiren KM, et al. Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol. 2005;242:1-9. (Pubitemid 41393704)
309. Cizza G, Ravn P, Chrousos GP, et al. Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol Metab. 2001;12:198-203. (Pubitemid 33714205)
310. Spangler L, Scholes D, Brunner RL, et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med. 2008;23:567-574.
311. Reginster JY, Deroisy R, Paul I, et al. Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas. 1999;33:133-137. (Pubitemid 29509933)
312. Whitson HE, Sanders L, Pieper CF, et al. Depressive symptomatology and fracture risk in community-dwelling older men and women. Aging Clin Exp Res. 2008;20:585-592.
313. Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303-1307. (Pubitemid 28195906)
314. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007; 67:1246-1251. (Pubitemid 46998495)
315. Jorde R, Sneve M, Figenschau Y, et al. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med. 2008;264:599-609.
316. Howland RH. Vitamin D and depression. J Psychosoc Nurs Ment Health Serv. 2011;49:15-18.
317. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182:1864-1873.